CURE7h
Evolving Treatments and Advances in HER2-Positive Breast Cancer
Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...
pharmaphorum7mon
NICE blocks Enhertu use after pricing talks break down
NICE and drugmakers AstraZeneca and Daiichi Sankyo have all expressed their disappointment at being unable to agree on a price for Enhertu that would allow it to be used on the NHS for people with ...
Cure Today1mon
Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer
Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...
BioSpace16d
AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...
London South East1mon
AstraZeneca's and Daiichi Sankyo's Enhertu wins new approval in US
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday celebrated another approval of their cancer drug Enhertu. The Cambridge, England-based and Tokyo-based pharmaceutical ...